Fresenius And Aurobindo Among Fresh Velcade Challengers In US
Launches Confirmed Of Subcutaneous Bortezomib Generics As Patents Set To Expire
Multiple firms have launched bortezomib products for subcutaneous administration in the US, adding to competition on Takeda’s Velcade brand.
You may also be interested in...
German pharma giant Fresenius Kabi has introduced a copay scheme for a number of its generic oncology medicines in the US, which could completely eliminate monthly costs for certain patients.
Fresenius Kabi has realised plans to launch its 505(b)(2) hybrid bortezomib 3.5mg/vial injectable in the US, after announcing the availability of the “first and only” alternative to Takeda’s Velcade (bortezomib) intravenous injectable.
Following decisions by the EMA’s CHMP to deny Prestige Biopharma a marketing authorization for its trastuzumab biosimilar and to suspend the marketing authorizations of dozens of generics due to concerns over bioequivalence tests, the European regulator has confirmed it will review the opinions.